Hjem
Martinez labben

Nyhetsarkiv for Martinez labben

A new study from the University in Bergen may shed light on the comorbidities found in adults suffering from this rare disease.
An important European-funded initiative has been launched to explore how common molecular mechanisms may link metabolic disorders, especially type 2 diabetes and obesity, with brain disorders such as Alzheimer's disease, obsessive-compulsive disorder, and autism spectrum disorders. Jan Haavik and Aurora Martinez from the Department of Biomedicine are the norwegian participants.
Martinez and collaborators are developing a pharmacological chaperone therapy for acute intermittent porphyria
The structure of full-length phenylalanine hydroxylase in complex with the cofactor BH4 is presented in the most recent issue of PNAS. As the cofactor is also used as a therapy for PKU, this structure is of medical importance.
Researchers from the lab of Aurora Martinez describe a novel mechanism for the degradation of enzymes involved in phenylketonuria and other neurometabolic disorders.
I forskergruppen Biogjenkjenning og firmaet Pluvia forsker de på enzymet som er ødelagt i pasienter med Føllings sykdom. I en artikkel i Aftenposten Viten beskriver forsker Marte Innselset Flydal hvordan de vil lage "molekylære krykker" som skal hjelpe enzymet til å fungere bedre.
The Workshop in Applied Structural Bioinformatics will be organized at the University of Bergen October 16-20. This workshop will provide a practical introduction to popular tools for biomolecular visualisation, analysis and simulations. Lectures will be given by both international and local speakers from the research fields of structural bioinformatics and computer-aided drug design.
Sarsia Seed recently announced their new seed funds in Bergen consisting of 300 million NOK. Initial investment can be in the biotechnology company Pluvia founded by Prof. Aurora Martinez according to Sarsia officials.
PhD-candidate Oscar Aubi Catevilla will defend his thesis: “Discovery of small-molecule activity modulators of bacterial and human phenylalanine hydroxylase”
Auroras work at USC highlighted in the J1 Newsletter.
Bio3D-web is a new online tool for the analyses of sequence, structure and conformational heterogeneity of protein families. The tool is developed by researcher Dr. Lars Skjærven, member of the the Biorecognition group, in collaboration with Prof. Barry J. Grant at the University of Michigan.
The Bio3D package includes new methods for the analysis and visualization of protein dynamics both from experimental and simulated data, integrated with tools for comparative analysis of evolutionary related protein structures and systematic retrieval of publicly available sequence and structural data.
The Biorecognition group at the Department of Biomedicine represents one of the four nodes in the new NOR-Openscreen infrastructure. The infrastructure will support the discovery of biologically active substances in all areas of the Life Sciences by providing transnational, open access to the most advanced technologies, chemical and biological resources as well as expertise through Europe.